title: [Non-upper aerodigestive tract NK/T- cell lymphoma: an analysis of clinical features and survival from a single center in China].
abstract: OBJECTIVE
  To analyze clinical features and outcomes of non-upper aerodigestive tract NK/T-cell lymphoma (NUAT-NKTCL).
  
  
  METHODS
  Clinical data of 44 patients with NUAT-NKTCL diagnosed at Peking University Cancer Hospital between 1999 and 2013 were retrospectively analyzed.
  
  
  RESULTS
  Of the 44 patients, there were 31 males and 13 females with a median age of 39 years (range, 15 to 82 years). 27 patients (61.4%) were stage III/IV, 28(63.6%) with B symptoms, 12(27.3%) ECOG ≥ 2, 18 (40.9%) IPI score ≥ 3, and 48.8% patients had elevated serum lactate dehydrogenase. The common primary sites were skin (21/44, 47.2%) and intestinal tract (11/44, 25.0%). All the 44 patients received systemic chemotherapy. After a median follow-up of 13.5 months (range, 0.3-121.0 months), 32 patients died, and the median overall survival (OS) was 16 months with 1-year OS rate as 54.1%. CR rate of the 26 patients received CHOP or CHOPE regimens as the first line chemotherapy was 19.2% (5/26). Then L-asparaginase (L-ASP)- based regimens were used for salvage treatment, with CR rate of 47.7% and the median OS of 13 months. CR rate of the other 18 patients received L-ASP-based regimens in the firstline therapy was 55.6% (10/18) with the median OS of 16 months. Using L-ASP in firstline treatment obviously improved CR rate (P=0.015), but did not affect OS (P=0.774).
  
  
  CONCLUSIONS
  Although L-ASP improved the efficacy of NUAT-NKTCL, but the prognosis remained dismal. Thus, more effective treatment strategies are required for NUAT-NKTCL.
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Ningjing
authors: N
authors: Lin
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Yuqin
authors: Y
authors: Song
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Wen
authors: W
authors: Zheng
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Meifeng
authors: M
authors: Tu
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Yan
authors: Y
authors: Xie
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Xiaopei
authors: X
authors: Wang
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Zhitao
authors: Z
authors: Ying
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Lingyan
authors: L
authors: Ping
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Chen
authors: C
authors: Zhang
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Weiping
authors: W
authors: Liu
authors: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors: Jun
authors: J
authors: Zhu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D001215:Asparaginase; D003520:Cyclophosphamide; D004317:Doxorubicin; D005047:Etoposide; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine; D055815:Young Adult
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone
references: J Clin Gastroenterol. 2013 Sep;47(8):e74-9
references: 23948755
references: J Clin Oncol. 2011 Nov 20;29(33):4410-6
references: 21990393
references: Ann Hematol. 2009 Jul;88(7):647-52
references: 19107482
references: J Clin Oncol. 2006 Feb 1;24(4):612-8
references: 16380410
references: J Clin Oncol. 2007 Feb 10;25(5):579-86
references: 17242396
references: Eur J Cancer. 2005 Jul;41(10):1402-8
references: 15963893
references: J Clin Oncol. 2009 Dec 10;27(35):6027-32
references: 19884539
references: J Hematol Oncol. 2013 Nov 16;6:86
references: 24238138
references: Cancer. 2012 Jul 1;118(13):3294-301
references: 22139825
references: J Hematol Oncol. 2013 Jul 01;6:44
references: 23816178
references: Eur J Haematol. 2012 Aug;89(2):103-10
references: 22553935
references: Blood. 2009 Apr 23;113(17):3931-7
references: 19029440
references: Cancer. 2013 Jan 15;119(2):348-55
references: 22811078
references: Blood. 2011 Feb 10;117(6):1834-9
references: 21123825
references: J Clin Oncol. 2009 Nov 20;27(33):5594-600
references: 19805668